MedDataX Logo

Effects of Recurrent PE on Women and Offspring

NCT ID: NCT05134285

Last Updated: 2021-12-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-01-31

Study Completion Date

2024-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the risk factors of recurrent preeclampsia and compare the short-term and long-term adverse outcomes of women and their offspring.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators collected women delivered twice in a row in our hospital. The investigators divided these pregnant women into three groups. Women in the first group did not complicate preeclampsia at both deliveries; Women in the second group complicated preeclampsia at the first delivery or at the second delivery; women in the third group complicated preeclampsia at two deliveries. The investigators explore the risk factors of recurrent preeclampsia and measure blood pressure, blood lipids, thyroid function, glycosylated hemoglobin, ALT, AST, et al. in one year, three years, and five years after the second delivery.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Preeclampsia Recurrence Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

control

pregnancy without preeclampsia

blood pressure,BMI, blood sample

Intervention Type OTHER

Blood pressure will be monitored. BMI will be measured. Blood samples will be tested.

preeclampsia

pregnancy complicated with preeclampsia at the first delivery or at the second delivery

blood pressure,BMI, blood sample

Intervention Type OTHER

Blood pressure will be monitored. BMI will be measured. Blood samples will be tested.

recurrent preeclampsia

pregnancy complicated with preeclampsia at two deliveries

blood pressure,BMI, blood sample

Intervention Type OTHER

Blood pressure will be monitored. BMI will be measured. Blood samples will be tested.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

blood pressure,BMI, blood sample

Blood pressure will be monitored. BMI will be measured. Blood samples will be tested.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* women with at least twice of delivery history

Exclusion Criteria

* women with chronic hypertension
Minimum Eligible Age

19 Years

Maximum Eligible Age

50 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Dunjin Chen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dunjin Chen

Director

Responsibility Role SPONSOR_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Obstetrics and Gynecology, Key Laboratory for Major Obstetric Diseases of Guangdong Province, The Third Affiliated Hospital of Guangzhou Medical University

Guangzhou, , China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Dunjin Chen

Role: CONTACT

Phone: 18928916722

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Dunjin Chen

Role: primary

Lili Du

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

81830045

Identifier Type: -

Identifier Source: org_study_id